Ferda BİR, Gamze GOKOZ DOGU, Yeliz ARMAN KARAKAYA, Sevin BASER ONCEL, Aysegul GORMEZ

Evaluation of survival and treatment correlation with ERCC-1 expression/amplification in Non-small cell carcinoma

Aim: The excision repair cross-complementation group 1 (ERCC-1) protein is a potential prognostic biomarker of the efficacy of platinum-based chemotherapy in non–small-cell lung cancer (NSCLC). The purpose of this study was to evaluate the clinicopathology and prognostic significance of ERCC-1 expression, ERCC-1 (19q13) amplification in NSCLC patients; and the relationship between platinum-based chemotherapy. Materials and Methods: We used the ERCC-1 antibody to measure the level of expression of ERCC-1 protein by immunohistochemical analysis from 351 patients and ERCC-1 gene copy number was evaluated by fluorescence in situ hybridization (FISH) in tumors from 81 patients. Results: ERCC-1 expression in tumor cells was positive in 312 patients (88.9%). The ERCC-1 amplification in tumor cells was positive in 58 patients (71.6%) out of 81. The ERCC-1 amplification was also more frequent in early-stage tumors than late-stage tumors (p = 0.025). In the patients with positive ERCC-1 expression, longer overall survival was associated with early stage NSCLC (p = 0.001). Patients having adenocarcinoma with negative ERCC-1 expression demonstrated longer overall survival than patients with squamous cell carcinoma (p = 0.037). Conclusion: Our study demonstrated that increased ERCC-1 amplification is not associated with ERCC-1 protein expression. High ERCC-1 expression in patients with early-stage NSCLC is a good prognostic factor, although it is a negative predictor, indicating treatment resistance, in patients with advanced-stage NSCLC receiving platinum-based chemotherapy. We suggest that patients having adenocarcinoma with negative ERCC-1 expression benefit more with platinum-based chemotherapies.

PDF

___

1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2016. National Cancer Institute 2019.
2. Jeong YH, Lee C kun, Jo K, et al. Correlation Analysis and Prognostic Impact of 18F-FDG PET and Excision Repair Cross-Complementation Group 1 (ERCC-1) Expression in Non-Small Cell Lung Cancer. Nucl Med Mol Imaging 2015;49:108-14.
3. Taillade L, Penault-Llorca F, Boulet T, et al. Immunohistochemichal expression of biomarkers: A comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer. Ann Oncol 2007;18:1043-50.
4. Bilen N, Tekin SB, Topdagi O. ERCC1 expression in non-small cell lung cancer and esophageal cancer. Eurasian J Med 2014;46:84-8.
5. Vanhecke E, Valent A, Tang X, et al. 19q13-ERCC1 gene copy number increase in non-small-cell lung cancer. Clin Lung Cancer 2013;14:549-57.
6. Andrews TD, Baird JW, Wallace WAH, et al. Routinely obtained diagnostic material as a source of rna for personalized medicine in lung cancer patients. J Thorac Oncol 2011;6:884-8.
7. Bogush TA, Dudko EA, Grishanina AN, et al. Flow cytometric analysis of the ERCC1, marker of DNA damage repair, in the tumor specimens embedded into paraffin blocks. Dokl Biochem Biophys 2017;472:9- 11.
8. Shen H, Zhu Y, Wu Y jie, et al. Genomic alterations in lung adenocarcinomas detected by multicolor fluorescence in situ hybridization and comparative genomic hybridization. Cancer Genet Cytogenet 2008;181:100-7.
9. Li J, Zhang W, Guo N, et al. Expression of molecular markers in primary sites and metastatic lymph nodes of lung cancer patients. Med Sci Monit 2017;23:513- 20.
10. Liao WY, Ho CC, Tsai TH, et al. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum. Lung Cancer 2018;118:90-6.
11. Yildiz OO, Celik IA. Methastatic N2 in T1 Non-small cell lug cancer: Should we go back to invasive staging? Ann Med Res 2020;27:1616-20.
12. Hubner RA, Riley RD, Billingham LJ, et al. Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: A meta-analysis of published studies and recommendations. PLoS One 2011;6:1-10.
13. Aiello MM, Solinas C, Santoni M, et al. Excision Repair Cross Complementation Group 1 Single Nucleotide Polymorphisms and Nivolumab in Advanced NonSmall Cell Lung Cancer. Front Oncol 2020;10:1167.
14. Villalobos M, Czapiewski P, Reinmuth N, et al. ERCC1 assessment in upfront treatment with and without cisplatin-based chemotherapy in stage IIIB/IV nonsquamous non-small cell lung cancer. Med Oncol 2018;35:106.
15. Jiang J, Liang X, Zhou X, et al. ERCC1 expression as a prognostic and predictive factor in patients with nonsmall cell lung cancer: A meta-analysis. Mol Biol Rep 2012;39:6933-42.
16. Ceppi P, Volante M, Novello S, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006;17:1818-25.
17. Simon GR, Sharma S, Cantor A, et al. ERCC1 expression is a predictor of survival in resected patients with nonsmall cell lung cancer. Chest. 2005;127:978-83.
18. Honma HN, Perroud MW, Morcillo AM, et al. Response to cytotoxic chemotherapy and overall survival in non-small cell lung cancer patients with positive or negative ERCC1 expression. J Bras Pneumol 2018;44:245-6.
19. Breen D, Barlési F. The place of excision repair cross complementation 1 (ERCC1) in surgically treated non-small cell lung cancer. Eur J Cardiothorac Surg 2008;33:805-11.
20. Lee SM, Falzon M, Blackhall F, et al. Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced NonSmall-Cell Lung Cancer: ERCC1 Trial (ET). J Clin Oncol 2017;35:402-11.
21. Aiello MM, Solinas C, Santoni M, et al. Aiello MM, Solinas C, Santoni M, et al. Excision Repair Cross Complementation Group 1 Single Nucleotide Polymorphisms and Nivolumab in Advanced NonSmall Cell Lung Cancer. Front Oncol 2020;10:1167. Published 2020 Sep 2.